Diabetes Clinical Trials in Honolulu
View 16 new treatments for Diabetes in Honolulu, HI. Every day, Power helps hundreds of Diabetes patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Metformin for Prediabetes
Research Clinic, Honolulu + 1 more
This trial is testing whether metformin can lower the risk of death, heart attacks, and strokes in people with pre-diabetes and heart or blood vessel issues. Metformin is a drug that helps control blood sugar levels and has been used to treat type 2 diabetes mellitus for more than 60 years. The study involves patients who have pre-diabetes and existing heart or blood vessel problems, aiming to see if metformin can provide additional health benefits.Show More
Recruiting
Phase 4
Est. 4 - 6 Weeks
Gregory G. Schwartz, PhD MD
Study Chair
Ranibizumab PDS Implant for Diabetic Retinopathy
Hoffmann-La Roche Clinic, 'Aiea + 1 more
Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DME) to Evaluate the Efficacy, Safety of the Port Delivery System with Ranibizumab (PDS) Relative to the Comparator ArmShow More
Waitlist
No Placebo Trial
Phase 3
Est. 4 - 6 Weeks
Clinical Trials
Study Director
Retatrutide vs Semaglutide for Type 2 Diabetes
Eli Lilly Clinic, Honolulu + 1 more
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 4 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Orforglipron for Obesity
Eli Lilly Clinic, Honolulu + 1 more
This trial will test a daily pill called orforglipron to see if it helps people who are overweight or obese and have type 2 diabetes lose weight. The study will last over a year and involve multiple visits.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
BI 456906 for Diabetes and Obesity
Boehringer Ingelheim Clinic, Honolulu + 1 more
This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesity who also have diabetes to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff. The doctors check participants' health and take note of any unwanted effects. The study staff also regularly measure participants' body weight. The results are compared between the groups to see whether the treatment works.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team
Tirzepatide vs Dulaglutide for Type 2 Diabetes
Eli Lilly Clinic, Honolulu + 3 more
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
IcoSema for Type 2 Diabetes
Novo Nordisk Clinic, Honolulu + 2 more
This trial will test a new weekly injection called IcoSema, which combines two drugs, in people with type 2 diabetes. The goal is to see if it controls blood sugar better than the existing drug, semaglutide. Participants will be randomly assigned to receive either IcoSema or semaglutide for several months.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 4 - 6 Weeks
Clinical Transparency (dept. 1452)
Study Director
Retatrutide for Type 2 Diabetes and Obesity
Eli Lilly Clinic, Honolulu + 1 more
This trial is testing retatrutide, a medication for people with type 2 diabetes who are overweight or obese, including some with sleep apnea. The medication aims to help control blood sugar levels and may also aid in weight loss.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Web-Based Physical Activity for Childhood Cancer Survivor Health
Research Clinic, Honolulu + 1 more
This randomized clinical phase III trial studies how well web-based physical activity intervention works in improving long term health in children and adolescents with cancer. Regular physical activity after receiving treatment for cancer may help to maintain a healthy weight and improve energy levels and overall health.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Kirsten K Ness
Principal Investigator
CagriSema for Type 2 Diabetes
Novo Nordisk Clinic, Honolulu + 1 more
This trial tests CagriSema, a combination of semaglutide and cagrilintide, in people with type 2 diabetes. It aims to see if it can better manage blood sugar levels and reduce body weight by increasing insulin and reducing hunger. Semaglutide is known for lowering blood glucose levels and reducing appetite.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Clinical Transparency (dept. 2834)
Study Director
Page 1 of 2
Frequently Asked Questions
Explore related conditions